Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909985 | 1.00 | SOS1 (0.65) | SOS1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4347026 | 0.82 | SOS1 (0.66) | SOS1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4914275 | 0.82 | SOS1 (0.66) | SOS1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4352713 | 0.81 | ALDH1A1 (0.69) | SOS1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4914308 | 0.81 | ALDH1A1 (0.69) | SOS1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4338966 | 0.81 | SOS1 (0.75) | SOS1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4338972 | 0.81 | SOS1 (0.75) | SOS1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4916464 | 0.79 | SOS1 (1.00) | SOS1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4916452 | 0.79 | SOS1 (1.00) | SOS1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4345025 | 0.78 | ALDH1A1 (1.00) | SOS1ALDH1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124919-A2 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-12-02 | — | — | EP | claimed |
| US-20080318987-A1 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | claimed |
| WO-2008103314-A2 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-08-28 | — | — | WO | claimed |
| EP-2124919-A2 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080318987-A1 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| WO-2008103314-A2 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318987-A1 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | BMP4, BMP2, SOST | SOS1 1864/4885ALDH1A1 3934/4885CYP1A2 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.